BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Castro MV, Lopez-Bergami P. Cellular and Molecular Mechanisms Implicated in the Dual Role of ROR2 in Cancer. Crit Rev Oncol Hematol 2022;:103595. [PMID: 35032666 DOI: 10.1016/j.critrevonc.2022.103595] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Lopez-Bergami P. ROR2, a driver of "phenotype switching" in melanoma? Cancer Cell Int 2022;22:288. [PMID: 36127680 DOI: 10.1186/s12935-022-02711-x] [Reference Citation Analysis]
2 Raivola J, Dini A, Salokas K, Karvonen H, Niininen W, Piki E, Varjosalo M, Ungureanu D. New insights into the molecular mechanisms of ROR1, ROR2, and PTK7 signaling from the proteomics and pharmacological modulation of ROR1 interactome. Cell Mol Life Sci 2022;79:276. [PMID: 35504983 DOI: 10.1007/s00018-022-04301-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Castro MV, Barbero GA, Máscolo P, Ramos R, Quezada MJ, Lopez-Bergami P. ROR2 increases the chemoresistance of melanoma by regulating p53 and Bcl2-family proteins via ERK hyperactivation. Cell Mol Biol Lett 2022;27:23. [PMID: 35260073 DOI: 10.1186/s11658-022-00327-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]